Replimune Group Analyst Ratings
Replimune Group Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 152.65% | HC Wainwright & Co. | $51 → $50 | Maintains | Buy |
| 08/01/2023 | 157.71% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 06/15/2023 | 152.65% | JP Morgan | $38 → $50 | Maintains | Overweight |
| 06/08/2023 | 157.71% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 06/07/2023 | 162.76% | Wedbush | → $52 | Reiterates | Outperform → Outperform |
| 06/07/2023 | 203.18% | EF Hutton | → $60 | Reiterates | Buy → Buy |
| 06/05/2023 | 157.71% | HC Wainwright & Co. | $50 → $51 | Maintains | Buy |
| 06/05/2023 | 203.18% | EF Hutton | → $60 | Reiterates | Buy → Buy |
| 05/26/2023 | 203.18% | EF Hutton | → $60 | Reiterates | Buy → Buy |
| 05/22/2023 | 162.76% | Wedbush | → $52 | Reiterates | Outperform → Outperform |
| 04/17/2023 | 122.33% | Piper Sandler | → $44 | Assumes | → Overweight |
| 02/10/2023 | 152.65% | HC Wainwright & Co. | $48 → $50 | Reiterates | → Buy |
| 01/05/2023 | 203.18% | EF Hutton | → $60 | Initiates Coverage On | → Buy |
| 12/12/2022 | 253.71% | BMO Capital | $40 → $70 | Maintains | Outperform |
| 12/07/2022 | 71.8% | SVB Leerink | $30 → $34 | Maintains | Outperform |
| 11/04/2022 | 142.55% | HC Wainwright & Co. | $60 → $48 | Maintains | Buy |
| 10/14/2022 | 102.12% | BMO Capital | $30 → $40 | Maintains | Outperform |
| 10/03/2022 | 51.59% | SVB Leerink | $37 → $30 | Maintains | Outperform |
| 08/16/2022 | 117.28% | Piper Sandler | $44 → $43 | Maintains | Overweight |
| 08/05/2022 | 86.96% | SVB Leerink | $48 → $37 | Maintains | Outperform |
| 05/24/2022 | 162.76% | Wedbush | $59 → $52 | Maintains | Outperform |
| 05/20/2022 | 142.55% | SVB Leerink | $49 → $48 | Maintains | Outperform |
| 04/04/2022 | 97.07% | JP Morgan | $47 → $39 | Maintains | Overweight |
| 03/18/2022 | 51.59% | BMO Capital | $51 → $30 | Maintains | Outperform |
| 11/19/2021 | 162.76% | Piper Sandler | → $52 | Initiates Coverage On | → Overweight |
| 08/23/2021 | 147.6% | SVB Leerink | $55 → $49 | Maintains | Outperform |
| 08/09/2021 | 177.92% | SVB Leerink | $56 → $55 | Maintains | Outperform |
| 02/05/2021 | 203.18% | HC Wainwright & Co. | $58 → $60 | Maintains | Buy |
| 02/04/2021 | 182.97% | SVB Leerink | $57 → $56 | Maintains | Outperform |
| 11/17/2020 | 203.18% | BTIG | → $60 | Initiates Coverage On | → Buy |
| 11/10/2020 | 193.08% | HC Wainwright & Co. | $54 → $58 | Maintains | Buy |
| 11/06/2020 | 188.02% | BMO Capital | $51 → $57 | Maintains | Outperform |
| 10/15/2020 | 157.71% | BMO Capital | $40 → $51 | Maintains | Outperform |
| 10/15/2020 | 172.87% | HC Wainwright & Co. | $25 → $54 | Upgrades | Neutral → Buy |
| 10/15/2020 | 122.33% | SVB Leerink | $27 → $44 | Maintains | Outperform |
| 08/07/2020 | 36.43% | SVB Leerink | $25 → $27 | Maintains | Outperform |
| 07/01/2020 | 26.33% | HC Wainwright & Co. | → $25 | Downgrades | Buy → Neutral |
| 06/04/2020 | 26.33% | HC Wainwright & Co. | $24 → $25 | Maintains | Buy |
| 05/05/2020 | 6.11% | Barclays | → $21 | Initiates Coverage On | → Overweight |
| 01/21/2020 | 21.27% | HC Wainwright & Co. | $26 → $24 | Maintains | Buy |
| 09/04/2019 | 1.06% | Roth Capital | → $20 | Initiates Coverage On | → Buy |
| 07/23/2019 | 41.49% | Chardan Capital | → $28 | Initiates Coverage On | → Buy |
| 07/12/2019 | 31.38% | JP Morgan | $27 → $26 | Upgrades | Neutral → Overweight |
| 07/08/2019 | 31.38% | HC Wainwright & Co. | → $26 | Initiates Coverage On | → Buy |
| 04/25/2019 | 21.27% | Wedbush | → $24 | Initiates Coverage On | → Outperform |
| 01/23/2019 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 08/14/2018 | 56.64% | BMO Capital | → $31 | Initiates Coverage On | → Outperform |
| 08/14/2018 | 31.38% | JP Morgan | → $26 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/07/2023 | 152.65% | HC Wainwright公司 | $51→$50 | 維護 | 買 |
| 08/01/2023 | 157.71% | HC Wainwright公司 | →$51 | 重申 | 購買→購買 |
| 2023/06/15 | 152.65% | 摩根大通 | $38→$50 | 維護 | 超重 |
| 06/08/2023 | 157.71% | HC Wainwright公司 | →$51 | 重申 | 購買→購買 |
| 06/07/2023 | 162.76% | 韋德布什 | →$52 | 重申 | 跑贏→跑贏大盤 |
| 06/07/2023 | 203.18% | EF Hutton | →$60 | 重申 | 購買→購買 |
| 06/05/2023 | 157.71% | HC Wainwright公司 | $50→$51 | 維護 | 買 |
| 06/05/2023 | 203.18% | EF Hutton | →$60 | 重申 | 購買→購買 |
| 2023年05月26日 | 203.18% | EF Hutton | →$60 | 重申 | 購買→購買 |
| 2023年05月22日 | 162.76% | 韋德布什 | →$52 | 重申 | 跑贏→跑贏大盤 |
| 04/17/2023 | 122.33% | 派珀·桑德勒 | →$44 | 假設 | →超重 |
| 02/10/2023 | 152.65% | HC Wainwright公司 | $48→$50 | 重申 | →購買 |
| 01/05/2023 | 203.18% | EF Hutton | →$60 | 開始承保 | →購買 |
| 2022年12月12日 | 253.71% | 蒙特利爾銀行資本 | $40→$70 | 維護 | 跑贏大盤 |
| 12/07/2022 | 71.8% | SVB Leerink | $30→$34 | 維護 | 跑贏大盤 |
| 11/04/2022 | 142.55% | HC Wainwright公司 | $60→$48 | 維護 | 買 |
| 10/14/2022 | 102.12% | 蒙特利爾銀行資本 | $30→$40 | 維護 | 跑贏大盤 |
| 10/03/2022 | 51.59% | SVB Leerink | $37→$30 | 維護 | 跑贏大盤 |
| 08/16/2022 | 117.28% | 派珀·桑德勒 | $44→$43 | 維護 | 超重 |
| 08/05/2022 | 86.96% | SVB Leerink | $48→$37 | 維護 | 跑贏大盤 |
| 2022年05月24日 | 162.76% | 韋德布什 | $59→$52 | 維護 | 跑贏大盤 |
| 05/20/2022 | 142.55% | SVB Leerink | $49→$48 | 維護 | 跑贏大盤 |
| 04/04/2022 | 97.07% | 摩根大通 | $47→$39 | 維護 | 超重 |
| 03/18/2022 | 51.59% | 蒙特利爾銀行資本 | $51→$30 | 維護 | 跑贏大盤 |
| 2021年11月19日 | 162.76% | 派珀·桑德勒 | →$52 | 開始承保 | →超重 |
| 2021/08/23 | 147.6% | SVB Leerink | $55→$49 | 維護 | 跑贏大盤 |
| 08/09/2021 | 177.92% | SVB Leerink | $56→$55 | 維護 | 跑贏大盤 |
| 02/05/2021 | 203.18% | HC Wainwright公司 | $58→$60 | 維護 | 買 |
| 02/04/2021 | 182.97% | SVB Leerink | $57→$56 | 維護 | 跑贏大盤 |
| 11/17/2020 | 203.18% | BTIG | →$60 | 開始承保 | →購買 |
| 11/10/2020 | 193.08% | HC Wainwright公司 | $54→$58 | 維護 | 買 |
| 11/06/2020 | 188.02% | 蒙特利爾銀行資本 | $51→$57 | 維護 | 跑贏大盤 |
| 10/15/2020 | 157.71% | 蒙特利爾銀行資本 | $40→$51 | 維護 | 跑贏大盤 |
| 10/15/2020 | 172.87% | HC Wainwright公司 | $25→$54 | 升級 | 中性→購買 |
| 10/15/2020 | 122.33% | SVB Leerink | $27→$44 | 維護 | 跑贏大盤 |
| 08/07/2020 | 36.43% | SVB Leerink | $25→$27 | 維護 | 跑贏大盤 |
| 07/01/2020 | 26.33% | HC Wainwright公司 | →$25 | 評級下調 | 購買→中性 |
| 06/04/2020 | 26.33% | HC Wainwright公司 | $24→$25 | 維護 | 買 |
| 05/05/2020 | 6.11% | 巴克萊 | →$21 | 開始承保 | →超重 |
| 2020/01/21 | 21.27% | HC Wainwright公司 | $26→$24 | 維護 | 買 |
| 2019年09月04日 | 1.06% | 羅斯資本 | →$20 | 開始承保 | →購買 |
| 2019年07月23日 | 41.49% | 查爾丹資本 | →$28 | 開始承保 | →購買 |
| 2019年07月12日 | 31.38% | 摩根大通 | $27→$26 | 升級 | 中性→超重 |
| 2019年07月08日 | 31.38% | HC Wainwright公司 | →$26 | 開始承保 | →購買 |
| 2019年04月25日 | 21.27% | 韋德布什 | →$24 | 開始承保 | →跑贏大盤 |
| 2019年01月23日 | - | 摩根大通 | 評級下調 | 超重→中性 | |
| 2018年08月14日 | 56.64% | 蒙特利爾銀行資本 | →$31 | 開始承保 | →跑贏大盤 |
| 2018年08月14日 | 31.38% | 摩根大通 | →$26 | 開始承保 | →超重 |
What is the target price for Replimune Group (REPL)?
Replimune Group(REPL)的目標價是多少？
The latest price target for Replimune Group (NASDAQ: REPL) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $50.00 expecting REPL to rise to within 12 months (a possible 152.65% upside). 19 analyst firms have reported ratings in the last year.
複製集團(納斯達克代碼：REPL)的最新目標價是由HC Wainwright&Co.於2023年8月7日報道的。這家分析公司將目標價定為50美元，預計每股收益將在12個月內升至(可能上漲152.65)。去年有19家分析公司公佈了評級。
What is the most recent analyst rating for Replimune Group (REPL)?
Replimune Group(REPL)的最新分析師評級是多少？
The latest analyst rating for Replimune Group (NASDAQ: REPL) was provided by HC Wainwright & Co., and Replimune Group maintained their buy rating.
對複製集團(納斯達克代碼：REPL)的最新分析師評級由HC Wainwright&Co.提供，複製集團維持其買入評級。
When is the next analyst rating going to be posted or updated for Replimune Group (REPL)?
Replimune Group(REPL)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Replimune Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Replimune Group was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Replimune Group的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Replimune Group的上一次評級是在2023年8月7日提交的，因此您應該預計下一次評級將在2024年8月7日左右提供。
Is the Analyst Rating Replimune Group (REPL) correct?
分析師評級Replimune Group(REPL)正確嗎？
While ratings are subjective and will change, the latest Replimune Group (REPL) rating was a maintained with a price target of $51.00 to $50.00. The current price Replimune Group (REPL) is trading at is $19.79, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Replimune Group(REPL)評級保持不變，目標價在51.00美元至50.00美元之間。Replimune Group(REPL)目前的交易價格為19.79美元，超出了分析師的預測區間。